{"prompt": "['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 31 of 88', 'Table 3', 'Exit Form reasons for discontinuation', 'Pregnancy:', 'Withdraw the Subject from the clinical trial and follow the procedure described in', 'Section 7.2.2.2.5.', 'Lack of Efficacy:', 'Investigator judgment only: based on therapeutic/disease-state expectations. If subject', 'opinion only, mark \"subject request\" and document it in the comment section of the Exit', 'Form.', 'Adverse Event:', 'Complete an Adverse Event Form.', 'Subject Requesta:', 'Includes consent withdrawal, subject relocation, schedule conflicts. Explain the reason for', 'withdrawal in the comment section of the Exit Form. If a subject withdraws consent', 'because of an adverse event, the reason for discontinuation should be Adverse Event', 'Protocol Violation:', 'Explain the violation in the comment section of the Exit Form.', 'Lost to Follow-up:', 'Confirmed with two documented phone calls and a certified letter (delivery receipt', 'requested) without answer. Explain in the comment section of the Exit Form.', 'Othera:', 'This category is to be used for a subject who discontinues due to a reason other than as', 'specified in the predefined categories above. Explain the reason for discontinuation in the', 'comment section of the Exit Form.', 'a) If reason for discontinuation is \"subject request\" or \"other\", the subject will be questioned to rule out the possibility of an AE (this', 'should be documented in the comment section of the Exit Form).']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 32 of 88', '6', 'CLINICAL SUPPLIES', '6.1', 'Clinical supply identification and use', '6.1.1', 'Study drug description', 'Table 4', 'Description and usage of the study drug', 'Investigational Product', 'Trade Name or Equivalent', 'N/A', 'Name of Drug Substance', 'Trifarotene', 'Internal Code', 'CCI', 'Pharmaceutical Form', 'Cream', 'Strength/ Concentration', '50 g/g', 'CCI', 'Location of Treated', 'Face and truncal region', 'CCI', 'Area', 'CCI', 'N/A=not applicable']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 33 of 88', '6.1.2', 'Subject identification number', 'Upon signature of the ICF (and Assent for minor subjects) each subject will be assigned a Subject', 'Identification Number (SIN) by the designated study personnel.', 'CCI', '6.1.3', 'Kit number', 'The kit number, a unique number corresponding to the number on the label of the study drug, will', 'be assigned to each eligible subject at Baseline.', 'CCI', 'CCI', '6.1.4', 'Instructions for use and application', 'Each subject will receive both oral and written instructions for the proper dosing and study', 'treatment application techniques.', 'CCI', 'As well, the dosing calendar completion will be explained to each', 'subject at each dispensation visit.', 'Applications will be done by the subjects themselves at home in the evening.', 'CCI', 'Application on the face:', 'CCI']\n\n###\n\n", "completion": "END"}